This protocol addresses a well-defined clinical scenario: estrogen receptor-positive ductal carcinoma in situ (DCIS) of the breast occurring in a postmenopausal patient. Double-blind randomised controlled trial evidence directly informs the adjuvant management approach in this population.
Postmenopausal status with hormone receptor (estrogen receptor)-positive ductal carcinoma in situ of the breast following breast-conserving surgery. Two double-blind RCTs have specifically evaluated systemic adjuvant options in this patient population after BCS, providing a direct evidence base for therapy selection.
The evidence-based approach for this scenario centres on adjuvant endocrine therapy initiated after breast-conserving surgery. The full structured protocol — including the specific agents supported by trial evidence, selection criteria, and sequencing guidance — is available via the link below.
DOI: 10.1093/jjco/hyae122
Two double-blind RCTs of anastrozole versus tamoxifen for postmenopausal women with ER-positive DCIS after BCS have been reported.
Based on these studies, both tamoxifen and anastrozole could be considered as being useful therapeutic options after BCS for postmenopausal women with hormone receptor-positive DCIS.
View source ↗